Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results

@article{Yoon2012QuantitativeIV,
  title={Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results},
  author={Miyoung Yoon and Jerry L. Campbell and Melvin E. Andersen and Harvey J. Clewell},
  journal={Critical Reviews in Toxicology},
  year={2012},
  volume={42},
  pages={633 - 652}
}
The field of toxicology is currently undergoing a global paradigm shift to use of in vitro approaches for assessing the risks of chemicals and drugs in a more mechanistic and high throughput manner than current approaches relying primarily on in vivo testing. However, reliance on in vitro data entails a number of new challenges associated with translating the in vitro results to corresponding in vivo exposures. Physiologically based pharmacokinetic (PBPK) modeling provides an effective… Expand
Biotransformation in vitro: An essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data.
TLDR
The current status of in vitro metabolism studies for QIVIVE extrapolation, serving today's hazard and risk assessment needs is discussed and the need for more streamlined and explicitly described integrated approaches to reflect the physiology and the related dynamic and kinetic processes of the human body is highlighted. Expand
Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds.
TLDR
There appears to be a systematic bias in the estimation of intrinsic clearance (Clint) from in vitro versus in vivo data, with in vitro based estimates underestimating in vivo clearance for smallvalues of Clint but with the opposite relationship at large values of Clint. Expand
Use of Physiologically Based Kinetic Modeling-Based Reverse Dosimetry to Predict in Vivo Toxicity from in Vitro Data.
TLDR
Since proofs-of-principle available so far have been provided for the prediction of toxicity in experimental animals, future research should focus on the use of in vitro toxicity data obtained in human models to predict the human situation using human PBK models to facilitate human- instead of experimental animal-based approaches in risk assessment. Expand
Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation
TLDR
The process of in vitro to in vivo extrapolation (IVIVE) to develop PBPK models for a chemical in different ages in order to predict the target tissue exposure at the age of concern in humans is described. Expand
Quantitative in Vitro-to-in Vivo Extrapolation for Mixtures: A Case Study of Superfund Priority List Pesticides.
TLDR
The importance of incorporating mixture-derived parameters into IVIVE for in vitro bioactivity data in order to accurately prioritize risks and facilitate science-based decision-making is demonstrated. Expand
Biokinetics and repeated exposure in in vitro assays : A detailed study into the behaviour of chlorpromazine and diazepam in different cell systems
TLDR
By studying the in vitro biokinetics of CPZ in different cell systems, it is found that the compound distributes over the different compartments present in an in vitro system: medium, cells and plastic. Expand
Species extrapolation of life-stage physiologically-based pharmacokinetic (PBPK) models to investigate the developmental toxicology of ethanol using in vitro to in vivo (IVIVE) methods.
TLDR
Benefits and challenges are demonstrated associated with use of multispecies PBPK models to estimate in vivo tissue concentrations associated with in vitro embryotoxicity studies and a model-supported linkage of in vitro concentrations with plausible exposure ranges for pregnant women is demonstrated. Expand
Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
TLDR
This case study with carbaryl provides a reasonably successful example of utilizing the in vitro to in vivo extrapolation (IVIVE) approach for PBPK model development, and can be applied to other carbamates with an anticholinesterase mode of action as well as to environmental chemicals in general with further refinement of the current shortcomings in the approach. Expand
The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans.
TLDR
A conceptual framework is presented for the incorporation of in vitro-derived toxicity data into the risk assessment process and the determination of a proper point-of-departure (PoD) forIn vitro-in vivo extrapolation, allowing implementation in risk assessment procedures. Expand
Tiered approaches for screening and prioritizing chemicals through integration of pharmacokinetics and exposure information with in vitro dose-response data
TLDR
A tiered approach to evaluate chemical risk is discussed that spans from qualitative screening of data-poor chemicals to quantitative modeling and prioritization ofData-rich chemicals, as well as how HT methods can be used to parameterize PK and PBPK models. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 122 REFERENCES
Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening.
Many chemicals in commerce today have undergone limited or no safety testing. To reduce the number of untested chemicals and prioritize limited testing resources, several governmental programs areExpand
Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment.
TLDR
The incorporation of dosimetry and exposure provide necessary context for interpretation of in vitro toxicity screening data and are important considerations in determining chemical testing priorities. Expand
The use of in vitro toxicity data and physiologically based kinetic modeling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man.
TLDR
An approach to predict in vivo dose-response curves for developmental toxicity by combining in vitro toxicity data and in silico kinetic modeling is shown, which could provide a means to reduce the need for animal testing in human risk assessment practices. Expand
Prediction of in vivo embryotoxic effect levels with a combination of in vitro studies and PBPK modelling.
TLDR
In vivo embryotoxicity of 5-fluorouracil was overestimated and a combination of in vitro and in silico techniques appears to be a promising alternative test method for risk assessment of embryotoxic compounds. Expand
Biokinetic Modeling and in Vitro–in Vivo Extrapolations
  • B. Blaauboer
  • Chemistry, Medicine
  • Journal of toxicology and environmental health. Part B, Critical reviews
  • 2010
TLDR
The introduction of in vitro methodologies in the toxicological risk assessment process requires a number of prerequisites regarding both the toxicodynamics and the biokinetics of the compounds under study, and the application of physiologically based biokinetic modelling is essential. Expand
Toxicodynamic modelling and the interpretation of in vitro toxicity data.
TLDR
In this study, biokinetic models were constructed, where possible, solely on the basis of in vitro derived parameters for biotransformation as well as on partition coefficients determined or calculated from physicochemical structures. Expand
Measuring, modeling, and increasing the free Concentration of test Chemicals in cell assays
Difficulties arise when extrapolating in vitro derived toxicity data to in vivo acute toxicity data because in vitro results are highly variable and occasionally less sensitive. Differences in theExpand
In vitro measurements of metabolism for application in pharmacokinetic modeling.
TLDR
This review focuses on the different organ, cellular, and subcellular systems that can be used to measure in vitro metabolic rate constants and how those data are extrapolated to be used in biologically based modeling. Expand
In vitro-in vivo extrapolation: estimation of human serum concentrations of chemicals equivalent to cytotoxic concentrations in vitro.
TLDR
An extrapolation model for estimating serum concentrations of chemicals equivalent to in vitro effective concentrations is developed and applied to median cytotoxic concentrations determined in vitro and suggests that estimates of equivalent serum concentrations based on in vitro data are robust for chemicals with low lipophilicity and low potency. Expand
Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
TLDR
Strategies for optimising in vivo predictions from in vitro data on metabolic stability and CYP inhibition are discussed and perspectives for future application and improvements in these predictions strategies are outlined. Expand
...
1
2
3
4
5
...